TADCLOT- a Double Blind Randomized Controlled Trial

Summary

Compare the safety and efficacy of a twice-daily Clopidogrel regimen vs. Ticagrelor in reducing major adverse events in patients undergoing primary PCI in a double-blind randomized controlled trial.

Timeline

Start

2024-02-19

Primary completion

2025-02-20

Completion

2025-02-20

Outcome

Missed primary endpoint

paper Ticagrelor was not superior to twice-daily clopidogrel in reducing MACEs at 1 month after primary PCI PMID 40892606 ↗

Publications

• Hakeem A, Shah JA, Kumar R, Ali A, Lakho AA, Zeeshan H, Uddin MI, Khan K, Solangi B, Kumar M, Kumar M, Awan R, Ishaq H, Farooq F, Haq EU, Hameed A, Lehri WA, Zada S, Ali A, Raza A, Masood S, Humza A, Karim M; TADCLOT Investigators. Twice-Daily Clopidogrel vs Ticagrelor to Reduce Short-Term Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention: The TADCLOT Trial. J Am Coll Cardiol. 2025 Dec 9;86(23):2330-2345. doi: 10.1016/j.jacc.2025.08.041. Epub 2025 Aug 30.
• Hakeem A, Ali Shah J, Kumar R, Khan K, Zeeshan H, Lakho AA, Ali A, Uddin MI, Solangi B, Kumar M, Kumar M, Awan R, Dilawar F, Ishaq H, Farooq F, Ul Haq E, Hameed A, Lehri WA, Zada S, Raza A, Masood S, Humza A, Karim M. Rationale and design of the TADCLOT trial: A double blind randomized controlled trial comparing twice a day clopidogrel vs ticagrelor in reducing major cardiac events in patients with acute STEMI undergoing primary percutaneous coronary intervention. Am Heart J. 2025 Sep;287:141-150. doi: 10.1016/j.ahj.2025.03.021. Epub 2025 Apr 12.

Drugs

Indications